Literature DB >> 34629768

Procurement of lungs from brain-dead donors.

Prasad Krishnan1, Sahar-Al-Sadat Sahar Saddoughi1.   

Abstract

Lung transplantation is the procedure of choice in many patients with end-stage lung disease and is being performed more frequently around the world. However, there continues to be shortage of donor organs with the ever-expanding number of recipients on the waiting list, leading to liberalization of the lung donor selection criteria with increasing acceptance of marginal donors while striving for excellent results. This has placed an increasing emphasis on the technique of donor lung procurement and preservation from marginal donors. Good judgment and procurement techniques are necessary to obtain high-quality donor lungs for transplantation and optimize long-term results. This is a review of our current technique used for the procurement of the lungs from brain-dead donors. © Indian Association of Cardiovascular-Thoracic Surgeons 2021.

Entities:  

Keywords:  Donor evaluation; Lung preservation; Lung procurement; Marginal donors; Operative techniques; Packing and transportation; Perfadex; Prostaglandin E-1; Pulmoplegia; Retrograde flushing; Transplantation

Year:  2021        PMID: 34629768      PMCID: PMC8464546          DOI: 10.1007/s12055-021-01140-1

Source DB:  PubMed          Journal:  Indian J Thorac Cardiovasc Surg        ISSN: 0970-9134


  25 in total

1.  Low-potassium dextran preservation solution improves lung function after human lung transplantation.

Authors:  S Fischer; A Matte-Martyn; M De Perrot; T K Waddell; Y Sekine; M Hutcheon; S Keshavjee
Journal:  J Thorac Cardiovasc Surg       Date:  2001-03       Impact factor: 5.209

Review 2.  Effects of drug abuse, smoking and alcohol on donor hearts and lungs.

Authors:  Guy A MacGowan; John H Dark; Paul A Corris; Arun R Nair
Journal:  Transpl Int       Date:  2019-06-28       Impact factor: 3.782

3.  Influence of donor and recipient age in lung transplantation.

Authors:  Don Hayes; Sylvester M Black; Joseph D Tobias; Robert S Higgins; Bryan A Whitson
Journal:  J Heart Lung Transplant       Date:  2014-09-01       Impact factor: 10.247

4.  Flush perfusion with low potassium dextran solution improves early graft function in clinical lung transplantation.

Authors:  M Strüber; M Wilhelmi; W Harringer; J Niedermeyer; M Anssar; A Künsebeck; J D Schmitto; A Haverich
Journal:  Eur J Cardiothorac Surg       Date:  2001-02       Impact factor: 4.191

5.  Lung procurement by low-potassium dextran and the effect on preservation injury. Munich Lung Transplant Group.

Authors:  C Müller; H Fürst; H Reichenspurner; J Briegel; J Groh; B Reichart
Journal:  Transplantation       Date:  1999-10-27       Impact factor: 4.939

6.  Influence of preservation solution on early graft failure in clinical lung transplantation.

Authors:  G Thabut; I Vinatier; O Brugière; G Lesèche; P Loirat; A Bisson; J Marty; M Fournier; H Mal
Journal:  Am J Respir Crit Care Med       Date:  2001-10-01       Impact factor: 21.405

7.  Prostaglandin E1 protects lung transplants from ischemia-reperfusion injury: a shift from pro- to anti-inflammatory cytokines.

Authors:  M de Perrot; S Fischer; M Liu; R Jin; X H Bai; T K Waddell; S Keshavjee
Journal:  Transplantation       Date:  2001-11-15       Impact factor: 4.939

8.  Low potassium dextran is superior to University of Wisconsin solution in high-risk lung transplant recipients.

Authors:  George J Arnaoutakis; Jeremiah G Allen; Christian A Merlo; William A Baumgartner; John V Conte; Ashish S Shah
Journal:  J Heart Lung Transplant       Date:  2010-07-14       Impact factor: 10.247

9.  Pulmonary graft preservation: a worldwide survey of current clinical practice.

Authors:  D N Hopkinson; M S Bhabra; T L Hooper
Journal:  J Heart Lung Transplant       Date:  1998-05       Impact factor: 10.247

10.  Influence of preservation solution on early lung function (Euro-Collins vs Perfadex).

Authors:  J M Rabanal; A M Ibañez; R Mons; A M Gonzalez; M Carbajo; J Ortega; F Zurbano
Journal:  Transplant Proc       Date:  2003-08       Impact factor: 1.066

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.